BRAF and melanoma: Specifically, resistance to treatment by small molecules has been reported to be developed through switching among the serine threonine kinase BRAF isoforms to activate the MAPK pathway [4], [6], a signaling network which plays a major role in proliferation and is a very attractive target for therapy due to the fact that it harbors somatic mutations in the majority of melanomas [7], [8].